Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coya TherapeuticsCOYA -3.10%49 Quick Ratio is 13.40 as of Jun. 2026, which is 52% above its 10-year median of 8.79. GuruFocus rates COYA with a GF Score™ of 49/100 and a GF Value™ of $6.54 (Significantly Undervalued). Among 1,409 Biotechnology companies, Coya Therapeutics ranks better than 85.52% on this metric.
Coya Therapeutics (NAS:COYA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Coya Therapeutics Quick Ratio Related Terms
Coya Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Coya Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Coya Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coya Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coya Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Coya Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Coya Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coya Therapeutics (COYA) has a Quick Ratio of 13.40 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Coya Therapeutics and its competitors. This is 52% above median its historical median of 8.79. Over the past decade, Coya Therapeutics' Quick Ratio has ranged from 1.88 to 19.57. According to the industry distribution chart, Coya Therapeutics ranks #204 out of 1409 companies in the Biotechnology industry, placing it in the top 14.5%.
Is Coya Therapeutics' Quick Ratio too high?
Coya Therapeutics' current Quick Ratio of 13.40 is 52% above median its 10-year median of 8.79. Over the past 10 years, this metric has ranged from a low of 1.88 to a high of 19.57. The Biotechnology industry median Quick Ratio is 3.60. Coya Therapeutics' value of 13.40 is 272.2% above this industry median. Based on the distribution chart, Coya Therapeutics ranks #204 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Coya Therapeutics has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coya Therapeutics' Quick Ratio compare to ONCY and GUTS?
According to the Biotechnology industry distribution chart, Coya Therapeutics ranks #204 out of 1409 companies for Quick Ratio. This places Coya Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Coya Therapeutics' value of 13.40 is 272.2% above this benchmark. Historically, Coya Therapeutics' own Quick Ratio has ranged from 1.88 to 19.57 over the past decade. While the company's 10-year median is 8.79 vs. the industry median of 3.60, Coya Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coya Therapeutics's current Quick Ratio of 13.40 is 272.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Coya Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coya Therapeutics's current Quick Ratio is 13.40, which is 52% above median its own 10-year median of 8.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coya Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Coya Therapeutics (COYA) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.54, compared to a current price of $4.39 — trading 32.9% below its estimated fair value. The current Quick Ratio is 13.40, which is 52% above median its 10-year median of 8.79 and 272.2% above the Biotechnology industry median of 3.60. Coya Therapeutics' overall GF Score™ is 49/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Coya Therapeutics (COYA), the current Quick Ratio is 13.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coya Therapeutics (COYA) Overvalued in 2026?
Based on GuruFocus' analysis, Coya Therapeutics stock appears to be undervalued.
The current stock price of $4.39 is trading 32.9% below its estimated GF Value™ of $6.54.
GuruFocus considers Coya Therapeutics to be Significantly Undervalued.
Key valuation signals for COYA:
Quick Ratio: 13.40 (52% above median its 10-year median of 8.79)
GF Value™: $6.54 vs. price of $4.39 (32.9% below fair value)
Industry Position: 272.2% above the Biotechnology median (#204 of 1409)
No single metric tells the full story. See the COYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
49GF Score
Get the complete analysis for COYA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COYA has been successfully added to your 
